Iguratimod

(Synonyms: T614)
5 Cited Publications
고객리뷰

Based on 5 publication(s) in Google Scholar

Iguratimod (T614) is an orally active anti-rheumatic agent. Iguratimod modulates T and B lymphocytes, inhibits the production of inflammatory cytokines and autoantibodies, and downregulates T cell-dependent cellular immunity. Iguratimod targets the IL-17 signaling axis, reduces MAPK phosphorylation and the mRNA stability of pro-inflammatory genes in fibroblast-like synoviocytes, and alleviates synovial inflammation in collagen-induced arthritis. Iguratimod blocks RANKL- and TNF-α-induced osteoclastogenesis by inhibiting the p38, ERK, and NF-κB signaling pathways, suppresses the bone resorption function of mature osteoclasts, and protects ovariectomized mice from bone loss. Iguratimod inhibits MIF tautomerase activity and exerts a steroid-sparing effect. Iguratimod inhibits COX-2, reduces PGE2 release, and also possesses anti-pulmonary fibrosis effects. Iguratimod can be used in research on various diseases such as rheumatoid arthritis, systemic lupus erythematosus, and interstitial lung disease.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity : 99.95%
  • CAS No.: 123663-49-0
  • 화학식: C17H14N2O6S
  • 분자량:374.37
  • 보관:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Biological Activity
  • Chemical Information
  • 용액&용해도
  • Protocol
  • 순도&문서
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

견적 받기 해외재고보유

Other size
견적 받기
Please select quantity
Amount: USD 0.00